Table 1 Baseline characteristics of patients with T2D who had undergone PAD revascularization taking SGLT2i or DPP4i before and after propensity score matching
| Â | Before PSM | After PSM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | SGLT2i | DPP4i | ASMD | SGLT2i | DPP4i | ASMD | ||||
|  | (n = 2,455) | (n = 8,695) |  | (n = 1,598) | (n = 1,598) |  | ||||
Age (mean) | 67.3 ± 11.0 | 70.8 ± 11.2 | 0.3166 | 67.5 ± 11.3 | 68.5 ± 10.9 | 0.0534 |  |  |  |  |
 < 65 | 961 | 39.14% | 2477 | 28.49% | 0.3217 | 550 | 34.42% | 541 | 33.85% | 0.0438 |
 65–74 | 815 | 33.20% | 2660 | 30.59% |  | 526 | 32.92% | 535 | 33.48% |  |
 75–84 | 556 | 22.65% | 2594 | 29.83% |  | 417 | 26.10% | 430 | 26.91% |  |
 > 85 | 123 | 5.01% | 964 | 11.09% |  | 105 | 6.57% | 92 | 5.76% |  |
Male | 1717 | 69.94% | 5120 | 58.88% | 0.2324 | 1073 | 67.15% | 1069 | 66.90% | 0.0053 |
Chronic liver disease | 326 | 13.28% | 1177 | 13.54% | 0.0076 | 207 | 12.95% | 216 | 13.52% | 0.0166 |
Chronic kidney disease | 863 | 35.15% | 5364 | 61.69% | 0.5507 | 650 | 40.68% | 600 | 37.55% | 0.0641 |
Congestive heart failure | 179 | 7.29% | 989 | 11.37% | 0.1407 | 110 | 6.88% | 102 | 6.38% | 0.0201 |
Hypertension | 2184 | 88.96% | 8065 | 92.75% | 0.1319 | 1422 | 88.99% | 1426 | 89.24% | 0.008 |
Dyslipidemia | 2130 | 86.76% | 6679 | 76.81% | 0.2599 | 1336 | 83.60% | 1358 | 84.98% | 0.0378 |
Ischemic stroke | 605 | 24.64% | 2047 | 23.54% | 0.0258 | 400 | 25.03% | 409 | 25.59% | 0.0129 |
Ischemic heart disease | 644 | 26.23% | 1599 | 18.39% | 0.1892 | 319 | 19.96% | 334 | 20.90% | 0.0233 |
Gout | 497 | 20.24% | 1907 | 21.93% | 0.0414 | 338 | 21.15% | 332 | 20.78% | 0.0092 |
Malignancy | 248 | 10.10% | 1084 | 12.47% | 0.0748 | 173 | 10.83% | 166 | 10.39% | 0.0142 |
PCI | 817 | 33.28% | 2382 | 27.40% | 0.1282 | 438 | 27.41% | 429 | 26.85% | 0.0127 |
CABG | 134 | 5.46% | 393 | 4.52% | 0.0431 | 70 | 4.38% | 66 | 4.13% | 0.0124 |
Diabetic medications | ||||||||||
 Use of metformin | 1217 | 49.57% | 2287 | 26.30% | 0.4939 | 801 | 50.13% | 862 | 53.94% | 0.0764 |
 Use of sulfonyurea | 1304 | 53.12% | 3274 | 37.65% | 0.3143 | 754 | 47.18% | 787 | 49.25% | 0.0413 |
 Use of glinides | 218 | 8.88% | 1971 | 22.67% | 0.3852 | 161 | 10.08% | 152 | 9.51% | 0.0189 |
 Use of acarbose | 342 | 13.93% | 898 | 10.33% | 0.1105 | 178 | 11.14% | 184 | 11.51% | 0.0118 |
 Use of glitazones | 374 | 15.23% | 488 | 5.61% | 0.3188 | 158 | 9.89% | 169 | 10.58% | 0.0227 |
 Use of insulin | 833 | 33.93% | 3985 | 45.83% | 0.2448 | 602 | 37.67% | 576 | 36.05% | 0.0337 |
CV medications | ||||||||||
 Use of APTs | 1834 | 74.70% | 6040 | 69.47% | 0.117 | 1157 | 72.40% | 1177 | 73.65% | 0.0282 |
 Use of ACEI/ARB | 1665 | 67.82% | 4925 | 56.64% | 0.2321 | 1053 | 65.89% | 1080 | 67.58% | 0.0359 |
 Use of amiodarone | 124 | 5.05% | 640 | 7.36% | 0.0958 | 75 | 4.69% | 82 | 5.13% | 0.0203 |
 Use of dronedarone | 4 | 0.16% | 19 | 0.22% | 0.0127 | 3 | 0.19% | 2 | 0.13% | 0.0158 |
 Use of beta-blocker | 1318 | 53.69% | 4102 | 47.18% | 0.1305 | 804 | 50.31% | 822 | 51.44% | 0.0225 |
 Use verapamil/diltiazem | 208 | 8.47% | 765 | 8.80% | 0.0116 | 132 | 8.26% | 130 | 8.14% | 0.0046 |
 Use of digoxin | 91 | 3.71% | 324 | 3.73% | 0.001 | 56 | 3.50% | 53 | 3.32% | 0.0103 |
 Use of statin | 1924 | 78.37% | 4590 | 52.79% | 0.559 | 1138 | 71.21% | 1202 | 75.22% | 0.0905 |
 Use of DOACs | 253 | 10.31% | 450 | 5.18% | 0.1928 | 144 | 9.01% | 156 | 9.76% | 0.0257 |
 Use of warfarin | 103 | 4.20% | 532 | 6.12% | 0.087 | 66 | 4.13% | 57 | 3.57% | 0.0293 |
 Use of loop diuretics | 501 | 20.41% | 1869 | 21.50% | 0.0267 | 308 | 19.27% | 318 | 19.90% | 0.0158 |
 Use of MRA | 304 | 12.38% | 685 | 7.88% | 0.1497 | 163 | 10.20% | 170 | 10.64% | 0.0143 |
 Use of ARNI | 70 | 2.85% | 51 | 0.59% | 0.1749 | 22 | 1.38% | 26 | 1.63% | 0.0206 |